Takahiro Einama

Dr. Takahiro Einama


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TETakahiro Einama
Takahiro Einama
YTYasuhiro Takihata
Yasuhiro Takihata
SASuefumi Aosasa
Suefumi Aosasa
FKFukumi Konno
Fukumi Konno
KKKazuki Kobayashi
Kazuki Kobayashi
YKYoji Kishi
Yoji Kishi
Although conversion surgery has increasingly been performed for initially unresectable advanced pancreatic ductal adenocarcinoma (PDAC), the rate of conversion, including that for patients who do not undergo resection, remains unclear. Patients with PDAC who were treated between January 2013 and December 2018 were classified into three groups: resectable (R), borderline resectable (BR), and unresectable (UR). We analyzed patient outcomes, including the rate of surgical resection and survival, in each of these groups. In total, 211 patients (R, 118; BR, 22; UR, 81) were selected. Among them, 117 (99%), 18 (82%), and 15 (19%) patients in the R, BR, and UR groups, respectively, underwent surgical resection. R0 resection rates were 88, 78, and 67%, whereas median overall survival (OS) from treatment initiation were 31, 18, and 11 months (p < 0.0001) in the R, BR, and UR groups, respectively. In patients who underwent surgical resection, relapse-free survival (RFS) and OS were similar among the three groups (R vs. BR vs. UR; median RFS (months), 17 vs. 13 vs. 11, p = 0.249; median OS (months), 31 vs. 26 vs. 32, p = 0.742). Lymph node metastases and incomplete adjuvant chemotherapy were identified as independent prognostic factors for OS. Although the surgical resection rate was low, particularly in the BR and UR groups, the prognosis of patients who underwent surgical resection was similar irrespective of the initial resectability status.

3 September 2020 in Oncology Letters
Verified
Journal Article
Open access
PDF file
TSTakafumi Suzuki
Takafumi Suzuki
YYYoji Yamagishi
Yoji Yamagishi
TETakahiro Einama
Takahiro Einama
TKTomomi Koiwai
Tomomi Koiwai
TYTamio Yamasaki
Tamio Yamasaki
HTHitoshi Tsuda
Hitoshi Tsuda
Mesothelin is expressed in various types of malignant tumors. The present study immunohistochemically investigated mesothelin expression and its clinicopathological significance in each subtype of breast cancer, with special reference to its cellular localization, in particular, membrane mesothelin expression. Using tissue specimens from 482 patients with breast cancer, immunohistochemistry was used to study mesothelin expression and help classify its localization as membrane or cytoplasmic expression. Mesothelin expression was detected in 77 (16.0%) cases and was the highest in triple‑negative breast cancer (31/75; 41.3%), followed by human epithelial growth factor receptor type 2 type (6/33, 18.2%) and luminal type (36/374; 9.6%). Among the 482 cases, membrane mesothelin expression was detected in 73 cases and was significantly associated with a negative hormone receptor status, higher Ki‑67 labeling index, nuclear grade 3 and a lower relapse‑free survival rate. Cytoplasmic mesothelin expression was not significantly associated with a lower relapse‑free survival rate (P=0.058). In the 343 cases of luminal type, the membrane mesothelin expression‑positive group had significantly worse prognosis than the membrane mesothelin‑expression‑negative group (P=0.042). There was no significant difference in the relapse‑free survival rate according to the membrane mesothelin expression status in the triple‑negative type and other types. It was suggested that membrane mesothelin expression in luminal type breast cancer is associated with a lower rate of relapse‑free survival.

29 October 2021 in Biomarker Research
Verified
Journal Article
Open access
PDF file
TETakahiro Einama
Takahiro Einama
YYYoji Yamagishi
Yoji Yamagishi
YTYasuhiro Takihata
Yasuhiro Takihata
TSTakafumi Suzuki
Takafumi Suzuki
TYTamio Yamasaki
Tamio Yamasaki
HTHitoshi Tsuda
Hitoshi Tsuda
The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-expression of mesothelin and CA125 in breast cancer. Our results showed that among 478 patients, mesothelin and CA125 were co-expressed in 48 (10 %), mesothelin only in 75 (16 %), CA125 only in 217 (45 %), and neither in 234 (49 %). A high correlation was observed between the expression of mesothelin and CA125 (P =0.0004). The co-expression of mesothelin and CA125 correlated with poor patient relapse-free survival (RFS) (P = 0.0001) and was identified as an independent predictor of RFS by Cox’s multivariate analysis. In conclusion, this is the first to report the prognostic significance of the co-expression of mesothelin and CA125 in breast cancer. The co-expression of mesothelin and CA125 may be clinically useful for prognostication after surgical therapy in patients with breast cancer.

28 May 2020 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
SKSoichiro Kakimoto
Soichiro Kakimoto
MMMorikazu Miyamoto
Morikazu Miyamoto
TETakahiro Einama
Takahiro Einama
HMHiroko Matsuura
Hiroko Matsuura
HIHideki Iwahashi
Hideki Iwahashi
MTMasashi Takano
Masashi Takano

28 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
TETakahiro Einama
Takahiro Einama
YYYoji Yamagishi
Yoji Yamagishi
YTYasuhiro Takihata
Yasuhiro Takihata
FKFukumi Konno
Fukumi Konno
KKKazuki Kobayashi
Kazuki Kobayashi
YKYoji Kishi
Yoji Kishi
We examined the value of preoperative dual time point (DTP) 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (FDG PET/CT) as a predictor of early recurrence or the outcomes in patients with pancreatic cancer. Standardized uptake values (SUVs) in DTP FDG PET/CT were performed as preoperative staging. SUVmax1 and SUVmax2 were obtained in 60 min and 120 min, respectively. ΔSUVmax% was defined as (SUVmax2 − SUVmax1)/SUVmax1 × 100. The optimal cut-off values for SUVmax parameters were selected based on tumor relapse within 1 year of surgery. Optimal cut-off values for SUVmax1 and ΔSUVmax% were 7.18 and 24.25, respectively. The combination of SUVmax1 and ΔSUVmax% showed higher specificity and sensitivity, and higher positive and negative predictive values for tumor relapse within 1 year than SUVmax1 alone. Relapse-free survival (RFS) was significantly worse in the subgroups of high SUVmax1 and high ΔSUVmax% (median 7.0 months) than in the other subgroups (p < 0.0001). The multivariate Cox analysis of RFS identified high SUVmax1 and high ΔSUVmax% as independent prognostic factors (p = 0.0060). DTP FDG PET/CT may effectively predict relapse in patients with pancreatic cancer. The combination of SUVmax1 and ΔSUVmax% identified early recurrent patient groups more precisely than SUVmax1 alone.

16 February 2021 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YSYuki Sota
Yuki Sota
TETakahiro Einama
Takahiro Einama
KKKazuki Kobayashibayashi
Kazuki Kobayashibayashi
IFIbuki Fujinuma
Ibuki Fujinuma
TTTakazumi Tsunenari
Takazumi Tsunenari
YKYoji Kishi
Yoji Kishi
Long‑term outcomes after surgical resection of bile duct cancer remain unsatisfactory, and survival, particularly after tumor recurrence, is poor. Gemcitabine and cisplatin combination (GC) therapy is the standard first‑line treatment; however, second‑line approaches are yet to be established. Radiotherapy may prolong the survival of patients with advanced biliary tract cancer, and particle radiotherapy delivers a more concentrated dose than conventional radiotherapy to deeper tumors. The present report describes the long‑term survival of a 65‑year‑old man with distal bile duct cancer of pathological stage IIA (T2N0M0; depth of invasion, 5.5 mm) following multimodal treatment. Following subtotal stomach‑preserving pancreatoduodenectomy, multiple hepatic recurrences were identified 9 months later, and GC therapy was initiated. The tumors were no longer evident 18 months later, and GC therapy was discontinued at the patient's request. A computed tomography (CT) scan performed 30 months after surgery identified a new solitary hepatic recurrence and duke pancreatic monoclonal antigen type‑2 (DUPAN‑2) levels were increased. Further GC therapy was declined. Carbon ion radiotherapy (CIRT) at a dose of 60 Gy [relative biological effectiveness (RBE)‑weighted absorbed dose] was then delivered in four fractions over 4 days [15 Gy (RBE)/day]. Tumor size decreased on CT, and fluorodeoxyglucose‑positron emission tomography/CT revealed a decline in the standardized uptake value of the tumor after 2 months, with decreased DUPAN‑2 levels. Following regrowth of the hepatic recurrence, CIRT was repeated at a dose of 66 Gy (RBE) in four fractions over 4 days [16.5 Gy (RBE)/day] and stable disease was maintained for 19 months. After 19 months, CT revealed tumor regrowth and another new metastatic lesion was identified in the left kidney. The patient received systematic chemotherapy again and died of the disease 81 months after the initial surgery. In conclusion, CIRT is a potential treatment option to control solitary recurrence of biliary tract cancer.